Intrathoracic Goiter in a Euthyroid Patient: Localization with125I and Study of Thyroidal Iodoproteins

1969 ◽  
Vol 29 (2) ◽  
pp. 183-190 ◽  
Author(s):  
GERALDO A. MEDEIROS-NETO ◽  
EDUARDO MANZANO ◽  
A. B. ULHOA CINTRA
2011 ◽  
Vol 25 (5) ◽  
pp. 518-521
Author(s):  
Hayato Abe ◽  
Shingo Ikeda ◽  
Haruaki Hino ◽  
Tatsuhiro Hoshino ◽  
Toshiya Yokota ◽  
...  

2014 ◽  
Vol 170 (1) ◽  
pp. 95-99 ◽  
Author(s):  
Carlo Cappelli ◽  
Ilenia Pirola ◽  
Elena Gandossi ◽  
Annamaria Formenti ◽  
Maurizio Castellano

ObjectiveTaking levothyroxine (l-T4) with coffee or with water followed by coffee intake within a few minutes results in poor TSH response in many patients. T4is available in tablet form worldwide, but novel formulations in soft gel capsule or liquid form are now available.DesignWe fortuitously identified a euthyroid patient who wrongly consumed liquidl-T4with coffee at breakfast; after changing the time of consumption to 30 min before breakfast, no change in TSH, free T4(fT4), and free tri-iodothyronine (fT3) concentrations was observed. Once the first patient was identified, additional stable euthyroid patients who consumed liquidl-T4with coffee were identified.MethodsPatients were recruited by searching our ‘thyroid patients’ database. All the patients on liquidl-T4treatment were contacted by phone to ask them whether they tookl-T4at breakfast. We identified 54 patients who were submitted to TSH, fT4, and fT3evaluation, with the indication that the same dosage ofl-T4be consumed 30 min before breakfast. We determined their TSH, fT4, and fT3concentrations after 3 and 6 months again.ResultsNo significant difference in thyroid hormone concentrations was observed in patients when they consumedl-T4at breakfast or when they consumed it 30 min before breakfast for 3 and 6 months (TSH: 2.5±1.1 vs 2.5±1.1 and 2.4±1.1 mIU/l respectively, fT4: 12.4±2.4 vs 12.5±2.4 and 12.3±2.1 pg/ml respectively, and fT3: 3.4±0.6 vs 3.4±0.6 and 3.3±0.5 pg/ml respectively).ConclusionOral liquidl-T4formulations could diminish the problem ofl-T4malabsorption caused by coffee when using traditional tablet formulations.


1987 ◽  
Vol 148 (3) ◽  
pp. 527-529 ◽  
Author(s):  
HM Park ◽  
RD Tarver ◽  
AR Siddiqui ◽  
DS Schauwecker ◽  
HN Wellman

2019 ◽  
Vol 14 (1) ◽  
pp. 22-26
Author(s):  
A.Yu. Ablicov ◽  
Yu.A. Ablicov ◽  
V.I. Vasilashko ◽  
P.A. Lukyanov

Author(s):  
Laszlo Hegedüs ◽  
Finn N. Bennedbæk

The main concern of patients and physicians alike, when dealing with the solitary thyroid nodule, is to diagnose the few cancers (approximately 5%) as rapidly and cost-effectively as possible, and to reduce superfluous thyroid surgery. Management has changed in recent years, but differences prevail as shown by an investigation among European thyroidologists (1). This chapter focuses on the palpably discrete swelling within an otherwise normal gland in the clinically and biochemically euthyroid patient (2, 3). The toxic nodule is dealt with in Chapter 3.3.11, and thyroid malignancy in Chapters 3.5.4–3.5.7.


1997 ◽  
Vol 3 (1) ◽  
pp. 14-18 ◽  
Author(s):  
Christopher R. McHenry, MD ◽  
Francisco Paras, Jr, MD ◽  
Yao-Chang Liu, MD ◽  
Mark Rodgers, MD

Sign in / Sign up

Export Citation Format

Share Document